文献速递心力衰竭与心肌病心律失常

扩张型心肌病心脏性猝死风险分层的无创标志物

Non-invasive markers for sudden cardiac death risk stratification in dilated cardiomyopathy.
PubMed 文献 · Heart · 2022-06-10

本文综述扩张型心肌病(DCM)心脏性猝死(SCD)风险分层的无创标志物。当前指南主要采用左心室射血分数和纽约心功能分级识别高危患者,但基于这些推荐的试验数据显示ICD恰当治疗的患者数量有限。文章在回顾现有指南导向标志物证据的基础上,探讨新的影像学、电生理和遗传学潜在风险标志物。

要点

  • 当前指南以左心室射血分数和纽约心功能分级作为DCM患者SCD风险分层的主要标志物。
  • 基于指南推荐的试验数据显示,ICD恰当治疗的患者数量有限,提示现有分层策略效果不足。
  • 综述探讨了影像学、电生理和遗传学等新的潜在无创风险标志物用于改善患者筛选。

核心结论

  • 当前以左心室射血分数和纽约心功能分级为主的SCD风险分层策略效果有限,基于此的试验中ICD恰当治疗的患者数量有限。
  • 需要新的影像学、电生理和遗传学无创标志物来更准确地识别最可能从ICD获益的DCM患者。

研究设计与样本

  • 综述文章,回顾当前指南导向的SCD风险标志物证据,并探讨新的潜在无创标志物。

主要发现

  • 分析支持当前指南推荐的试验数据发现,ICD恰当治疗的患者数量有限。
  • 许多患者不必要地承受ICD植入相关并发症,而另一些可预防死亡的患者未被识别。

关键数值与推荐

  • 当前指南推荐使用左心室射血分数和纽约心功能分级作为SCD风险分层的主要标志物。

临床怎么用

  • 临床应认识到现有指南推荐的SCD风险分层标志物存在局限,ICD患者选择需更精准。
  • 关注影像学、电生理和遗传学等新标志物的研究进展,以优化DCM患者的ICD植入决策。

局限性

  • 本文为综述,未报告新的原始研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dilated cardiomyopathy (DCM) is a common yet challenging cardiac disease. Great strides have been made in improving DCM prognosis due to heart failure but sudden cardiac death (SCD) due to ventricular arrhythmias remains significant and challenging to predict. High-risk patients can be effectively managed with implantable cardioverter defibrillators (ICDs) but because identification of what is high risk is very limited, many patients unnecessarily experience the morbidity associated with an ICD implant and many others are not identified and have preventable mortality. Current guidelines recommend use of left ventricular ejection fraction and New York Heart Association class as the main markers of risk stratification to identify patients who would be at higher risk of SCD. However, when analysing the data from the trials that these recommendations are based on, the number of patients in whom an ICD delivers appropriate therapy is modest. In order to improve the effectiveness of therapy with an ICD, the patients who are most likely to benefit need to be identified. This review article presents the evidence behind current guideline-directed SCD risk markers and then explores new potential imaging, electrophysiological and genetic risk markers for SCD in DCM.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Pooranachandran V, Nicolson W, Vali Z, et al. Non-invasive markers for sudden cardiac death risk stratification in dilated cardiomyopathy. Heart. 2022. PMID: 34670824. doi:10.1136/heartjnl-2021-319971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。